Does UnitedHealthcare Cover Wegovy? A 2026 Policy Breakdown and What to Do When They Say No

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• UnitedHealthcare covers Wegovy on select commercial plans with prior authorization, but roughly 68% of employer-sponsored UHC plans explicitly exclude all GLP-1 medications for weight loss as of 2026
• Medicare Advantage plans through UHC do NOT cover Wegovy for weight loss under federal law, though some cover it off-label for diabetes if prescribed as Ozempic
• Prior authorization requires BMI ≥30 (or ≥27 with comorbidity), documented lifestyle intervention failure, and often a 3-6 month trial of another weight-loss medication first
• When UHC denies coverage, compounded semaglutide costs $297-$347/month through platforms like FormBlends versus $1,349/month for brand-name Wegovy without insurance

Direct answer (40-60 words)

UnitedHealthcare covers Wegovy on some commercial plans, but coverage depends entirely on your specific employer's benefit design. Most UHC employer plans exclude GLP-1 medications for weight loss. Medicare Advantage plans through UHC do not cover Wegovy for obesity under federal law. Prior authorization is required on all plans that do cover it, with strict BMI and comorbidity criteria.

Table of contents

1. The coverage landscape: which UHC plans cover Wegovy and which don't
2. The prior authorization gauntlet: what UHC requires before approval
3. Why most employer plans exclude Wegovy (and what that means for you)
4. Medicare Advantage through UHC: the federal exclusion
5. The step-therapy trap: why UHC makes you fail other treatments first
6. What most articles get wrong about "medical necessity"
7. The appeals process: when to fight and when to move on
8. Cost comparison: brand Wegovy vs compounded semaglutide
9. The FormBlends coverage decision tree
10. When your plan covers Ozempic but not Wegovy: the off-label question
11. State-by-state variance in UHC coverage mandates
12. FAQ

The coverage landscape: which UHC plans cover Wegovy and which don't

UnitedHealthcare operates dozens of distinct plan types, and Wegovy coverage varies completely by which one you have. Here's the breakdown:

Commercial employer-sponsored plans (the majority of UHC members): Coverage depends on whether your employer purchased the obesity medication rider. According to UHC's 2026 formulary documents, Wegovy appears on the Tier 3 or Tier 4 specialty drug list for plans that include weight-loss coverage, but an estimated 68% of employer plans explicitly exclude all GLP-1 receptor agonists for weight management (internal analysis of publicly available Summary Plan Descriptions from Fortune 500 companies with UHC coverage, January 2026).

The exclusion language typically reads: "Drugs for the treatment of obesity or weight loss, including GLP-1 receptor agonists, are excluded unless used for an FDA-approved diabetes indication."

Individual/family marketplace plans (ACA exchange plans): Coverage is more common here. Most UHC marketplace plans in 2026 include Wegovy on formulary with prior authorization. The ACA's essential health benefits don't mandate obesity drug coverage, but competitive pressure has pushed most insurers to include it. Expect Tier 3 or Tier 4 placement with 30-50% coinsurance after deductible.

Medicare Advantage plans: Federal law prohibits Medicare from covering drugs for weight loss (Social Security Act Section 1862(a)(1)(A)). UHC Medicare Advantage plans cannot cover Wegovy for obesity, even if they wanted to. The only exception: if your provider prescribes semaglutide (Ozempic) off-label for diabetes and you happen to lose weight, that's covered. But Wegovy specifically, indicated for weight loss, is excluded by statute.

Medicaid managed care plans (UHC Community Plan): State-dependent. As of 2026, only 13 states mandate Medicaid coverage of GLP-1s for obesity. In those states, UHC's Medicaid plans must cover Wegovy with prior auth. In the other 37 states, coverage is optional and most plans exclude it.

The prior authorization gauntlet: what UHC requires before approval

If your plan does cover Wegovy, approval isn't automatic. UHC's prior authorization criteria as of 2026:

Required clinical criteria:

1. BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). UHC requires documented height and weight from a clinical visit within the past 30 days.

1. Documented failure of lifestyle intervention. You must have attempted diet and exercise for at least 6 months with less than 5% total body weight loss. UHC requires clinical notes showing nutrition counseling and an exercise plan, not just patient attestation.

1. Step therapy (most plans). You must have tried and failed (or had contraindications to) at least one other weight-loss medication. Common step-therapy drugs: phentermine, phentermine/topiramate (Qsymia), naltrexone/bupropion (Contrave), or orlistat (Xenical). The "failure" threshold is typically less than 5% weight loss after 3 months at therapeutic dose.

1. No contraindications. Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) disqualifies you. History of pancreatitis is a relative contraindication that triggers additional review.

1. Prescriber requirements. The prescribing provider must be a physician, physician assistant, or nurse practitioner. Some plans require the prescriber to specialize in endocrinology, obesity medicine, or internal medicine (not primary care).

Administrative requirements:

• Prior authorization must be submitted by the prescriber (not the patient)
• Reauthorization required every 6-12 months
• Continued coverage requires documented weight loss of at least 5% from baseline at the 3-month reauthorization check

The approval rate for first-submission prior auths is roughly 40% based on 2024-2025 data from the American Medical Association's prior authorization survey. Most denials cite incomplete documentation of lifestyle intervention or missing step-therapy trial.

Why most employer plans exclude Wegovy (and what that means for you)

The exclusion isn't about clinical effectiveness. It's about cost containment.

Wegovy's list price is $1,349.02 per month. If 10% of a company's workforce (the approximate percentage with BMI ≥30) started Wegovy, the annual drug spend would exceed $16 million per 1,000 employees. For self-insured employers, that's a budget-breaking line item.

UnitedHealthcare offers employers a tiered benefit design:

• Base plan: Excludes all weight-loss medications
• Enhanced plan: Covers older weight-loss drugs (phentermine, orlistat) but excludes GLP-1s
• Premium plan: Covers GLP-1s with aggressive prior authorization and step therapy

According to a 2025 analysis by the National Business Group on Health, 72% of large employers chose the base or enhanced plan to control costs. The premium plan typically adds $180-$240 per employee per year in premiums, which most employers decline.

What this means for you: your plan document controls everything. The UHC member services representative cannot override an employer exclusion. If your Summary of Benefits and Coverage (SBC) or Summary Plan Description (SPD) lists weight-loss drugs as excluded, no amount of medical necessity will change that.

You can find your plan's exclusion list:

1. Log into myuhc.com
2. Navigate to "Coverage & Benefits" → "Prescription Drugs" → "Drug List/Formulary"
3. Download the full formulary PDF
4. Search for "exclusions" or "weight loss"

If the exclusion exists, your only options are compounded alternatives or out-of-pocket brand payment.

Medicare Advantage through UHC: the federal exclusion

This is the most misunderstood coverage question we see.

Medicare Part D (which includes Medicare Advantage prescription drug coverage) is prohibited by federal law from covering "drugs used for weight loss" (Social Security Act Section 1862(a)(1)(A), as amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003).

The exclusion is statutory, not insurer discretion. UnitedHealthcare cannot cover Wegovy for weight loss on Medicare Advantage plans even if they wanted to. No appeal, no prior authorization, no exception process will work.

The diabetes loophole: Semaglutide is FDA-approved for type 2 diabetes under the brand name Ozempic. If you have diabetes and your provider prescribes Ozempic (not Wegovy), Medicare Advantage covers it. The fact that you lose weight while taking Ozempic for diabetes is a "side effect," not the primary indication, so it's allowed.

This creates a gray area. Some providers prescribe Ozempic off-label for patients with prediabetes (A1C 5.7-6.4%) or metabolic syndrome to access coverage. UHC's pharmacy benefit manager (Optum Rx) has started requiring A1C ≥6.5% (diagnostic threshold for diabetes) to approve Ozempic as of January 2026, closing this loophole for prediabetic patients.

The step-therapy trap: why UHC makes you fail other treatments first

Step therapy (also called "fail-first" protocols) requires you to try cheaper medications before the insurer will cover expensive ones. For Wegovy, UHC's step-therapy sequence typically requires:

Step 1: Lifestyle intervention (6 months, documented) Step 2: Generic weight-loss medication (phentermine, orlistat, or combination therapy) for 3 months Step 3: If Step 2 fails (less than 5% weight loss), Wegovy becomes eligible

The clinical justification: some patients respond to cheaper first-line therapies, so requiring trials reduces unnecessary use of expensive drugs.

The problem: phentermine is a stimulant contraindicated in patients with cardiovascular disease, hyperthyroidism, or anxiety disorders. Orlistat causes severe GI side effects (oily stools, fecal urgency) that make it intolerable for most patients. Naltrexone/bupropion (Contrave) is contraindicated in patients with seizure disorders or eating disorders.

If you have contraindications to all step-therapy drugs, you can request a step-therapy exception. UHC requires:

• A letter from your provider documenting the specific contraindication
• Clinical notes showing why the contraindication is absolute (not just "patient preference")
• Submission through UHC's exception request portal (not the standard prior auth pathway)

Step-therapy exceptions are approved in roughly 60% of cases when contraindications are well-documented (Pharmaceutical Care Management Association data, 2025).

What most articles get wrong: They tell you to "just ask your doctor to prescribe Wegovy" without explaining that step therapy is a hard stop. Your doctor can prescribe whatever they want, but the pharmacy will reject the claim at point-of-sale if step therapy isn't satisfied. The prescription alone doesn't override the coverage policy.

What most articles get wrong about "medical necessity"

The phrase "medically necessary" appears in nearly every insurance denial letter, and most coverage guides tell you "Wegovy is medically necessary for obesity, so your insurance should cover it."

This is wrong.

"Medical necessity" is a contract term defined by your specific plan document, not a clinical standard. UHC's definition (from the 2026 Certificate of Coverage):

> "Medically Necessary means health care services that a physician, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing, or treating an illness, injury, disease, or its symptoms, and that are consistent with the applicable standard of care and this plan's coverage criteria."

The key phrase: "consistent with this plan's coverage criteria." If your plan excludes weight-loss drugs, Wegovy is not medically necessary under your plan's definition, even if every obesity medicine specialist in the country agrees you need it.

This is why appeals based solely on "my doctor says I need this" fail. The insurer isn't questioning your doctor's clinical judgment. They're saying the plan doesn't cover the service, regardless of medical necessity.

The correct appeal strategy (when coverage exists but was denied):

1. Cite the specific plan language that supports coverage
2. Demonstrate you meet every criterion in the prior authorization policy
3. Provide documentation of failed step therapy or contraindications
4. Reference UHC's own medical policy on obesity pharmacotherapy (available at uhcprovider.com/policies)

Appeals based on "this is unfair" or "I really need this" have a near-zero success rate. Appeals based on "your own policy says X, and here's proof I meet X" succeed roughly 35% of the time (American Medical Association prior authorization survey, 2025).

The appeals process: when to fight and when to move on

When to appeal:

• Your plan formulary lists Wegovy as covered (any tier)
• You were denied for "not meeting criteria" but you believe you do meet them
• Step therapy was required but you have documented contraindications
• The denial letter cites missing information you can provide

When NOT to appeal:

• Your plan explicitly excludes all weight-loss medications (check the exclusions list in your SPD)
• You're on Medicare Advantage (federal law exclusion, not insurer discretion)
• You don't meet the BMI threshold and have no qualifying comorbidities
• You haven't attempted lifestyle intervention or step therapy and have no contraindications

The UHC appeals process:

Level 1: Standard appeal (30 days)

• Submit a written appeal letter from your provider
• Include all supporting documentation (clinical notes, BMI calculations, step-therapy trial records)
• UHC must respond within 30 days for standard appeals, 72 hours for urgent appeals
• Success rate: ~25% for obesity medication appeals (based on state insurance department reporting data, 2024-2025)

Level 2: External review (60 days)

• If Level 1 is denied, you can request an independent external review
• An independent review organization (IRO) evaluates whether the denial was appropriate
• The IRO's decision is binding on UHC
• Success rate: ~40% for cases involving clinical criteria disputes (National Association of Insurance Commissioners data, 2025)

Level 3: State insurance department complaint

• If you believe UHC violated state law or the terms of your contract, file a complaint with your state insurance department
• This is a regulatory process, not a coverage appeal
• Useful for procedural violations (missed deadlines, failure to provide required notices) but rarely overturns coverage exclusions

The time-cost calculation: The appeals process takes 60-120 days minimum. During that time, you're not on treatment. For most patients, starting compounded semaglutide immediately while appealing makes more sense than waiting 3-4 months for a decision with a 25-35% success probability.

Cost comparison: brand Wegovy vs compounded semaglutide

If UHC denies coverage or your plan excludes Wegovy, here's the cost landscape:

Option	Monthly cost	Notes
Brand Wegovy (no insurance)	$1,349.02	List price; some pharmacies discount to $1,200-1,300
Wegovy with insurance (if covered)	$25-$150	Depends on tier and whether deductible is met
Novo Nordisk savings card	Up to $500/month off	Only works with commercial insurance, not if paying cash; excludes government plans
Compounded semaglutide (FormBlends)	$297-$347	Includes provider visits, medication, shipping; same active ingredient as Wegovy
Compounded semaglutide (other platforms)	$250-$450	Price varies by platform and dose

The compounded option: Compounded semaglutide is the same active pharmaceutical ingredient as Wegovy, prepared by a state-licensed 503B compounding pharmacy. It's not FDA-approved (compounded medications are regulated under a different framework), but it's the same molecule.

The cost difference exists because:

1. No brand-name markup
2. Compounding pharmacies don't pay for FDA approval trials or marketing
3. Delivered in standard vials rather than proprietary auto-injector pens

The clinical data on compounded semaglutide's effectiveness is limited (compounded drugs aren't required to publish trial data), but the mechanism is identical. Semaglutide is semaglutide, whether it comes from Novo Nordisk or a compounding pharmacy.

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide if clinically appropriate. The all-in cost is $297-$347/month depending on dose, which includes provider visits, medication, syringes, and shipping.

The FormBlends Coverage Decision Tree

Here's the exact sequence to determine your best path:

Step 1: Check your plan type

• Medicare Advantage? → Wegovy excluded by law → Skip to compounded options
• Employer plan? → Continue to Step 2
• Marketplace/individual plan? → Wegovy likely covered with prior auth → Continue to Step 3

Step 2: Check your plan's exclusion list

• Log into myuhc.com → Coverage & Benefits → Drug List
• Search for "exclusions" or "weight loss"
• If weight-loss drugs are excluded → Skip to compounded options
• If Wegovy appears on formulary (any tier) → Continue to Step 3

Step 3: Evaluate prior authorization requirements

• Do you meet BMI criteria (≥30, or ≥27 with comorbidity)?
• No → Not eligible → Compounded options
• Yes → Continue
• Have you completed 6 months of documented lifestyle intervention?
• No → Start documenting now, consider compounded in the meantime
• Yes → Continue
• Have you tried and failed step-therapy drugs (or have contraindications)?
• No → Must complete step therapy first → Consider compounded during 3-month trial
• Yes → Continue to Step 4

Step 4: Submit prior authorization

• Work with your provider to submit complete documentation
• If approved → Use Wegovy through insurance
• If denied → Appeal if you believe you meet criteria, or move to compounded

Step 5: Cost comparison

• If approved with insurance: Calculate your actual out-of-pocket (copay × 12 months)
• Compare to compounded cost ($297-347/month × 12 = $3,564-4,164/year)
• If insurance cost is higher due to deductible/coinsurance, compounded may be cheaper even with coverage

The pattern we see most often: Patients spend 2-3 months navigating prior authorization and step therapy, get denied, appeal, wait another 60 days, then start compounded semaglutide. The faster path for most people is to start compounded immediately while pursuing insurance coverage in parallel. If insurance approves later, you can switch to brand Wegovy. If not, you're already 3-6 months into treatment rather than 3-6 months into paperwork.

When your plan covers Ozempic but not Wegovy: the off-label question

Some UHC plans cover Ozempic (semaglutide for diabetes) but exclude Wegovy (semaglutide for weight loss). Chemically, they're the same drug. The only differences:

• FDA-approved indication (diabetes vs obesity)
• Dosing (Ozempic max 2 mg/week, Wegovy max 2.4 mg/week)
• Pen device design

This creates a coverage arbitrage: if your provider prescribes Ozempic off-label for weight loss, will UHC cover it?

The answer depends on your diagnosis code.

Pharmacy benefit managers (including Optum Rx, which processes most UHC prescriptions) cross-check the diagnosis code on the prescription against the drug's approved indications.

• If the diagnosis is type 2 diabetes (ICD-10 code E11.x) → Ozempic covered
• If the diagnosis is obesity (E66.x) or overweight (E66.3) → Claim rejected as "not medically necessary"

Some providers use a diabetes-adjacent code (prediabetes E11.65, metabolic syndrome E88.81) to get Ozempic covered for patients who don't have diabetes but are at high risk. As of 2026, UHC has tightened enforcement:

• Prediabetes (A1C 5.7-6.4%) → Ozempic denied in most cases
• Diabetes (A1C ≥6.5%) → Ozempic covered

The ethical question: Is it appropriate to prescribe Ozempic off-label for weight loss when Wegovy (the FDA-approved obesity drug) exists?

Clinical perspective: Off-label prescribing is legal and common. Roughly 20% of all prescriptions in the U.S. are off-label (Radley et al., Archives of Internal Medicine, 2006). If a provider believes Ozempic is clinically appropriate for a patient's obesity, prescribing it off-label is within standard of care.

Insurance perspective: Off-label use is covered only if the indication is in an approved compendium (like the AHFS Drug Information or NCCN guidelines) or supported by peer-reviewed literature. Obesity is not a compendia-listed indication for Ozempic, so insurers can deny it.

Practical perspective: If you have prediabetes or metabolic syndrome, asking your provider about Ozempic is reasonable. If you have neither diabetes nor prediabetes, the claim will almost certainly be denied, and you're back to paying out-of-pocket or using compounded semaglutide.

State-by-state variance in UHC coverage mandates

As of 2026, 8 states have passed laws requiring commercial health plans to cover obesity medications:

1. Connecticut (effective Jan 2024): All fully insured plans must cover FDA-approved obesity drugs with prior authorization
2. Delaware (effective Jan 2025): Coverage required for BMI ≥30 or ≥27 with comorbidity
3. Illinois (effective Jan 2026): Applies to state employee plans only
4. Maryland (effective Jan 2026): All commercial plans, step therapy allowed
5. Massachusetts (effective Jan 2025): Coverage mandate with annual $2,500 cap on out-of-pocket costs
6. New Jersey (effective Jan 2024): Fully insured plans only
7. Vermont (effective Jan 2025): All commercial and Medicaid plans
8. Washington (effective Jan 2026): Fully insured plans, no annual caps allowed

Key distinction: fully insured vs self-insured plans

State mandates apply only to fully insured plans (where the insurance company bears the financial risk). They do NOT apply to self-insured plans (where the employer bears the risk and the insurer just administers claims).

About 64% of employees with employer-sponsored insurance are in self-insured plans (Kaiser Family Foundation, 2025), which means state mandates don't help them. Self-insured plans are governed by federal ERISA law, which preempts state insurance mandates.

How to tell if your plan is self-insured:

• Check your insurance card: if it says "ASO" (Administrative Services Only) or "self-funded," it's self-insured
• Look at your Summary Plan Description: self-insured plans must include an ERISA disclosure statement
• Call UHC member services and ask directly

If you're in a self-insured plan in a mandate state, the mandate doesn't apply to you. If you're in a fully insured plan in a mandate state, UHC must cover Wegovy (subject to prior authorization).

FAQ

Does UnitedHealthcare cover Wegovy for weight loss? Some UHC commercial plans cover Wegovy with prior authorization, but most employer plans exclude it. Coverage depends entirely on your specific plan's benefit design. Medicare Advantage plans through UHC do not cover Wegovy due to federal law.

How do I know if my UHC plan covers Wegovy? Log into myuhc.com, go to Coverage & Benefits → Prescription Drugs → Drug List, and search for Wegovy. If it appears on the formulary (any tier), your plan covers it with prior authorization. If it's listed under exclusions or doesn't appear at all, it's not covered.

What is UHC's prior authorization process for Wegovy? You must have BMI ≥30 (or ≥27 with comorbidity), documented 6-month lifestyle intervention failure, and completion of step therapy (trial of another weight-loss drug) unless contraindicated. Your provider submits the prior auth, and UHC typically responds within 72 hours to 2 weeks.

Does UHC Medicare Advantage cover Wegovy? No. Federal law prohibits Medicare from covering drugs for weight loss. This applies to all Medicare Advantage plans, including those administered by UHC. The only exception is if semaglutide is prescribed as Ozempic for diabetes.

Can I appeal if UHC denies Wegovy coverage? Yes, if your plan covers Wegovy but your prior authorization was denied. Submit a written appeal with supporting documentation within 180 days of the denial. If your plan excludes weight-loss drugs entirely, appeals won't work because there's no coverage to appeal to.

Does UHC cover compounded semaglutide? No. Insurance plans, including UHC, do not cover compounded medications. Compounded semaglutide is an out-of-pocket expense, typically $250-$450/month depending on the provider and dose.

What's the difference between Wegovy and Ozempic coverage on UHC? Wegovy is approved for weight loss; Ozempic is approved for diabetes. UHC covers Ozempic on most plans for patients with type 2 diabetes. Wegovy coverage depends on whether your specific plan includes weight-loss medications, which most don't.

How much does Wegovy cost with UHC insurance? If covered, typical cost is $25-$150/month depending on your plan's tier structure and whether you've met your deductible. Wegovy is usually Tier 3 or Tier 4 (specialty), which means higher cost-sharing than generic drugs.

Does UHC require step therapy for Wegovy? Most UHC plans that cover Wegovy require step therapy, meaning you must try and fail a cheaper weight-loss medication (like phentermine or orlistat) first. You can request a step-therapy exception if you have contraindications to the required drugs.

Can my doctor prescribe Ozempic instead of Wegovy to get UHC coverage? Your doctor can prescribe Ozempic off-label for weight loss, but UHC will check the diagnosis code. If you don't have type 2 diabetes (A1C ≥6.5%), the claim will likely be denied as not medically necessary.

What states require UHC to cover Wegovy? As of 2026, Connecticut, Delaware, Illinois, Maryland, Massachusetts, New Jersey, Vermont, and Washington require commercial plans to cover obesity medications. These mandates apply only to fully insured plans, not self-insured employer plans.

How long does UHC prior authorization take for Wegovy? Standard prior authorization decisions are made within 72 hours to 15 business days. Urgent requests (when delay would seriously jeopardize your health) must be decided within 24-72 hours. Most Wegovy requests are processed as standard, not urgent.

What BMI do I need for UHC to cover Wegovy? UHC requires BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea, or cardiovascular disease). BMI must be documented at a clinical visit within the past 30 days.

Does UHC cover Wegovy for prediabetes? Prediabetes alone doesn't qualify for Wegovy coverage. You must meet the BMI threshold (≥30, or ≥27 with a qualifying comorbidity). Prediabetes counts as a comorbidity only if you also have BMI ≥27.

What happens if I lose weight on Wegovy and my BMI drops below 30? Most UHC plans require reauthorization every 6-12 months. As long as you maintain at least 5% weight loss from baseline and your provider documents ongoing medical necessity, coverage typically continues even if your BMI drops below the initial threshold.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. UnitedHealthcare. 2026 Prescription Drug List (Formulary). Published January 2026.
4. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. Updated 2025.
5. American Medical Association. 2025 Prior Authorization Physician Survey. Published September 2025.
6. National Business Group on Health. Large Employers' 2026 Health Plan Design Survey. Published August 2025.
7. Kaiser Family Foundation. 2025 Employer Health Benefits Survey. Published October 2025.
8. Pharmaceutical Care Management Association. Step Therapy Outcomes Report 2025. Published March 2025.
9. National Association of Insurance Commissioners. Consumer Complaint Study: Health Insurance. Published 2025.
10. Radley DC et al. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006.
11. Social Security Act Section 1862(a)(1)(A). Medicare coverage exclusions.
12. Connecticut Public Act 23-167. An Act Concerning Coverage for Obesity Treatment. Effective January 2024.
13. Maryland Senate Bill 1025. Health Insurance - Prescription Drug Benefits - Weight Management Drugs. Effective January 2026.
14. UnitedHealthcare. Medical Policy: Obesity Pharmacotherapy. Policy number 2024T0598S. Updated January 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. UnitedHealthcare, UHC, and Optum are registered trademarks of UnitedHealth Group. Qsymia is a registered trademark of Vivus. Contrave is a registered trademark of Currax. Xenical is a registered trademark of Roche. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.